Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Massachusetts
Clinical trial register · United States · industry-sponsored

Clinical Trials in Massachusetts, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9132 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 11 Oct 2026, 03:16 UTC
9132
Studies in scope
industry-sponsored, all four open statuses
4964
Recruiting now
open to new participants
2194
Lead sponsors
across recruiting studies
Top states
California 45 Texas 33 Florida 32 New York 31 Massachusetts 25
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Trials with a site in Massachusetts

25 of 9132 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
I-Mab Biopharma US Limited
Phase 2
180
Arizona, California, Massachusetts
2026-02-11
Recruiting
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
NCT07300150Colorectal Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, Solid Tumor
PAQ Therapeutics, Inc.
Phase 1
210
Massachusetts, Texas, Utah, Virginia
2025-11-21
Recruiting
STORM Therapeutics LTD
Phase 1/2
107
California, Florida, Massachusetts, Michigan, New York, Ohio, Texas, Virginia
2025-05-05
Recruiting
A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
NCT06952010Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor, Immune Sensitive Tumor
Exelixis
Phase 1
303
California, Connecticut, Florida, Massachusetts, Missouri, New York, North Carolina, Tennessee
2025-05-01
Recruiting
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
NCT06810544Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme, Glioma, Malignant, Solid Tumor
Tango Therapeutics, Inc.
Phase 1/2
191
Arizona, California, District of Columbia, Florida, Illinois, Massachusetts, Minnesota, New York
2025-03-24
Recruiting
PAQ Therapeutics, Inc.
Phase 1
300
California, Massachusetts, Michigan, Tennessee, Texas, Utah, Virginia
2024-12-19
Recruiting
Genentech, Inc.
Phase 1
410
California, Colorado, Connecticut, Florida, Illinois, Massachusetts, Michigan, New York
2024-11-14
Recruiting
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
NCT06586957Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult, Metastatic Tumor
NiKang Therapeutics, Inc.
Phase 1
238
Arkansas, California, Colorado, Florida, Georgia, Kansas, Massachusetts, New Jersey
2024-09-19
Recruiting
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
NCT06425926Melanoma Stage IV, Solid Tumor
Georgiamune Inc
Phase 1/2
117
Arizona, California, Massachusetts, Montana, New York, Ohio, Tennessee, Virginia
2024-05-09
Recruiting
OnCusp Therapeutics, Inc.
Phase 1
263
Colorado, Connecticut, Florida, Massachusetts, Michigan, New York, Oklahoma, Tennessee
2024-02-09
Active, closed
Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
NCT06160752Locally Advanced Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Solid Tumor, Metastatic Cholangiocarcinoma
Tyra Biosciences, Inc
Phase 1
40
California, Massachusetts, Ohio, Texas
2023-11-22
Recruiting
FOG-001 in Locally Advanced or Metastatic Solid Tumors
NCT05919264Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor
Parabilis Medicines, Inc.
Phase 1/2
619
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Maryland, Massachusetts
2023-05-23
Active, closed
Study of PYX-106 in Solid Tumors
NCT05718557Solid Tumor
Pyxis Oncology, Inc
Phase 1
47
Arizona, California, Colorado, Georgia, Illinois, Massachusetts, Ohio, Rhode Island
2023-05-23
Recruiting
A Study of PYX-201 in Advanced Solid Tumors
NCT05720117Solid Tumor, Advanced Solid Tumor
Pyxis Oncology, Inc
Phase 1
330
Arizona, California, Colorado, Florida, Georgia, Illinois, Massachusetts, Missouri
2023-03-14
Active, closed
A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors
NCT05653882Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of Head and Neck
Asher Biotherapeutics, Inc.
Phase 1
552
California, Connecticut, Florida, Illinois, Massachusetts, Michigan, Missouri, New Jersey
2023-01-04
Active, closed
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
NCT05544552Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor, Urothelial Carcinoma
Tyra Biosciences, Inc
Phase 1/2
310
Massachusetts, New York, North Carolina, Ohio, Tennessee, Washington
2022-11-22
Recruiting
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
NCT05245500Mesothelioma, Non Small Cell Lung Cancer, Malignant Peripheral Nerve Sheath Tumors, Solid Tumor
Bristol-Myers Squibb
Phase 1
336
Arizona, Colorado, Florida, Illinois, Massachusetts, Michigan, Minnesota, New Jersey
2022-06-09
Recruiting
Astellas Pharma Inc
Phase 1
681
California, Colorado, Connecticut, District of Columbia, Florida, Kansas, Massachusetts, Michigan
2022-06-08
Recruiting
Simcha IL-18, Inc.
Phase 1/2
316
Arizona, Colorado, Connecticut, Florida, Massachusetts, New York
2021-08-06
Recruiting
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
NCT04900818Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer
I-Mab Biopharma US Limited
Phase 1
330
California, Colorado, Indiana, Massachusetts, New Jersey, New York, North Carolina, Tennessee
2021-06-29
Active, closed
IDEAYA Biosciences
Phase 1
169
Arizona, Arkansas, California, Florida, Indiana, Maryland, Massachusetts, New York
2021-04-14
Recruiting
A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
NCT04516447Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 1
172
Colorado, Massachusetts, Missouri, New York, North Carolina, Rhode Island, Tennessee, Texas
2020-10-26
Recruiting
ImmVira Pharma Co. Ltd
Phase 1/2
30
Arizona, Massachusetts, Pennsylvania, Texas, Virginia
2020-09-17
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
370
Colorado, Illinois, Massachusetts, New York, North Dakota, South Dakota, Texas
2015-03-19
Rows per page Showing 1–25 of 25
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-usa/state/massachusetts

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,132 studies in total at the last sync on 11 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 25 of those studies with a site in Massachusetts that also match the filters currently applied.

How many clinical trials are recruiting in Massachusetts?

19 of the 25 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 6 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Massachusetts), 25 studies
PhaseStudiesRecruitingShare
Phase 1161164%
Phase 1/28732%
Phase 2114%

Most active sponsors

Lead sponsors with the most studies (Massachusetts)
Lead sponsorStudiesRecruiting
Genentech, Inc.21
I-Mab Biopharma US Limited22
PAQ Therapeutics, Inc.22
Pyxis Oncology, Inc21
Tyra Biosciences, Inc20
Asher Biotherapeutics, Inc.10
Astellas Pharma Inc11
Bristol-Myers Squibb11
Exelixis11
Georgiamune Inc11
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.